Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alcoholic cirrhosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    58 result(s) found for: Alcoholic cirrhosis. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2011-006227-38 Sponsor Protocol Number: 11.017 Start Date*: 2012-05-01
    Sponsor Name:Ove B. Schaffalitzky de Muckadell
    Full Title: “Assessment of fibrotic liver disease in a medical admission ward and intervention with losartan as antifibrotic therapy in patients with alcoholic liverdisease”
    Medical condition: Fibrotic alcoholic liver disease is in early stages often completely asymptomatic. Fully developed cirrhosis affect a wide range of physiological conditions. Eksamples are portal hypertension and f...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10001627 Alcoholic liver disease PT
    14.1 10019805 - Hepatobiliary disorders 10001626 Alcoholic liver damage, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001454-24 Sponsor Protocol Number: IPSS B025-L Start Date*: 2005-06-08
    Sponsor Name:RIEMSER Arzneimittel AG
    Full Title: An Open Labelled, Clinical Phase II Study With Oral Cis-U-Hydroxy-L-Proline (CHP) in 45 Patients With: - Chronic viral hepatitis - Chronic alcoholic liver diseases without cirrhosis - Compens...
    Medical condition: Chronic viral hepatitis, Chronic alcoholic liver diseases without cirrhosis, Compensated alcoholic liver cirrhosis, Primary Billiary Cirrhosis or Primary Sclerosing Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    1.1 10019805 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010335-41 Sponsor Protocol Number: RRK3728 Start Date*: 2009-06-30
    Sponsor Name:University of Birmingham
    Full Title: A MULTICENTRE, PHASE II, OPEN LABEL, RANDOMISED CONTROLLED TRIAL OF REPEATED AUTOLOGOUS INFUSIONS OF G-CSF MOBILISED CD133+ BONE MARROW STEM CELLS IN PATIENTS WITH CIRRHOSIS
    Medical condition: Liver Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10001806 Alpha-1 anti-trypsin deficiency PT
    14.1 10019805 - Hepatobiliary disorders 10009211 Cirrhosis liver LLT
    14.1 10019805 - Hepatobiliary disorders 10024667 Liver cirrhosis LLT
    14.1 10019805 - Hepatobiliary disorders 10064844 Compensated cirrhosis LLT
    14.1 10019805 - Hepatobiliary disorders 10019641 Hepatic cirrhosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013897-42 Sponsor Protocol Number: RHMMED0883 Start Date*: 2010-04-27
    Sponsor Name:Southampton University Hospitals NHS Trust R&D department
    Full Title: STOPAH: STeroids Or Pentoxifylline for Alcoholic Hepatitis
    Medical condition: Severe alcoholic hepatitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004449-18 Sponsor Protocol Number: HEP201 Start Date*: 2019-04-10
    Sponsor Name:Promethera Biosciences
    Full Title: Multicenter, open-label, safety and tolerability study of ascending doses of HepaStem in patients with cirrhotic and pre-cirrhotic non-alcoholic steatohepatitis (NASH).
    Medical condition: NASH is characterized by steatosis, inflammation and cytological ballooning with varying amounts of fibrosis. Patients with NASH are at risk of cardiovascular morbidity and mortality. In chronic li...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10031743 Other chronic nonalcoholic liver disease LLT
    20.0 10019805 - Hepatobiliary disorders 10019708 Hepatic steatosis PT
    20.0 10019805 - Hepatobiliary disorders 10041970 Steatosis hepatic LLT
    20.0 10019805 - Hepatobiliary disorders 10019669 Hepatic fibrosis and cirrhosis HLT
    20.0 10019805 - Hepatobiliary disorders 10009211 Cirrhosis liver LLT
    20.0 10019805 - Hepatobiliary disorders 10024667 Liver cirrhosis LLT
    20.0 10019805 - Hepatobiliary disorders 10009213 Cirrhosis of liver LLT
    20.1 10019805 - Hepatobiliary disorders 10064704 Decompensated cirrhosis LLT
    20.1 10019805 - Hepatobiliary disorders 10064844 Compensated cirrhosis LLT
    20.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    20.0 10019805 - Hepatobiliary disorders 10076331 Steatohepatitis PT
    20.0 10019805 - Hepatobiliary disorders 10019641 Hepatic cirrhosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) BG (Completed) PL (Completed) ES (Ongoing) RO (Completed)
    Trial results: View results
    EudraCT Number: 2019-001969-33 Sponsor Protocol Number: TAK-242-2001 Start Date*: 2020-05-28
    Sponsor Name:Akaza Bioscience Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Proof-of-Concept, Phase 2a Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-242 in Subj...
    Medical condition: Acute Alcoholic Hepatitis Causing Decompensation of Alcohol related Cirrhosis and Acute-on-Chronic Liver Failure
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10001627 Alcoholic liver disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002489-11 Sponsor Protocol Number: GS-US-321-0106 Start Date*: 2013-02-26
    Sponsor Name:Gilead Sciences Inc
    Full Title: A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects w...
    Medical condition: Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-005008-16 Sponsor Protocol Number: STOPPIT-01 Start Date*: 2021-03-08
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Stop of proton-pump inhibitor treatment in patients with liver cirrhosis – a double-blind, placebo-controlled trial
    Medical condition: Liver cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10019641 Hepatic cirrhosis PT
    20.0 10019805 - Hepatobiliary disorders 10024667 Liver cirrhosis LLT
    20.0 10017947 - Gastrointestinal disorders 10003445 Ascites PT
    20.1 10021881 - Infections and infestations 10051156 Ascites infection LLT
    20.0 10021881 - Infections and infestations 10068547 Bacterascites PT
    20.0 10021881 - Infections and infestations 10068555 Monomicrobial non-neutrocytic bacterascites LLT
    24.1 10021881 - Infections and infestations 10061135 Spontaneous bacterial peritonitis PT
    21.1 10029205 - Nervous system disorders 10019660 Hepatic encephalopathy PT
    20.0 100000004866 10036201 Portal hypertensions HLT
    20.1 10019805 - Hepatobiliary disorders 10036200 Portal hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002488-88 Sponsor Protocol Number: GS-US-321-0105 Start Date*: 2013-07-29
    Sponsor Name:Gilead Sciences Inc
    Full Title: A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects w...
    Medical condition: Advanced Liver Fibrosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) DE (Prematurely Ended) GB (Prematurely Ended) ES (Completed) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000963-15 Sponsor Protocol Number: MATCH0.1 Start Date*: 2016-01-19
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: MAcrophage Therapy for Liver Cirrhosis (MATCH)
    Medical condition: Liver Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024667 Liver cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-002628-96 Sponsor Protocol Number: R-RID Start Date*: 2016-09-21
    Sponsor Name:Imperial College London
    Full Title: A multi-centre, double-blind, randomised, controlled clinical trial of Rifaximin to reduce infection in patients admitted to hospital with decompensated cirrhosis
    Medical condition: Decompensated cirrhosis - liver disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-003766-26 Sponsor Protocol Number: 25-12-59 Start Date*: 2009-10-12
    Sponsor Name:Southampton University Hospitals NHS Trust
    Full Title: The effects of purified n-3 fatty acids on serum biomarkers and cardiovascular risk markers in a randomized placebo controlled trial in patients with non alcoholic fatty liver disease
    Medical condition: Non alcoholic fatty liver disease (NAFLD). This fatty liver disease may progress to a chronic condition that sometimes deteriorates further to cirrhosis and even liver carcinoma. To date there is n...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10031743 Other chronic nonalcoholic liver disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004031-23 Sponsor Protocol Number: E2012AILIVER Start Date*: 2014-08-26
    Sponsor Name:Hopital Erasme
    Full Title: Serum pharmacokinetics of Caspofungin in patients with liver failure.
    Medical condition: The patient admitted for alcoholic hepatitis or decompensated cirrhosis (Child-Pugh score of 10-15) presenting with invasive aspergillosis (proven or probable) and treated by caspofungin.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004871 10024678 Liver failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004473-32 Sponsor Protocol Number: IDN-6556-14 Start Date*: 2016-12-27
    Sponsor Name:Conatus Pharmaceuticals Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hyperten...
    Medical condition: Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10036200 Portal hypertension PT
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004484-31 Sponsor Protocol Number: NN9931-4492 Start Date*: 2019-05-13
    Sponsor Name:Novo Nordisk A/S
    Full Title: Investigation of efficacy and safety of semaglutide s.c. once-weekly versus placebo in subjects with non-alcoholic steatohepatitis and compensated liver cirrhosis
    Medical condition: Non-alcoholic steatohepatitis Compensated liver cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    20.0 10019805 - Hepatobiliary disorders 10024667 Liver cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-002079-16 Sponsor Protocol Number: E2013_PK_CASPO70_LIVERFAILURE Start Date*: 2013-09-05
    Sponsor Name:Hospital Erasme
    Full Title: Pharmacokinetics of Caspofungin after one dose in patients with liver failure.
    Medical condition: The pharmacokinetics parameters of caspofungin will be studied for the patient admitted for alcoholic hepatitis or decompensated cirrhosis (Child-Pugh score 7-15).
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004871 10024678 Liver failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004419-24 Sponsor Protocol Number: RHMMED0687 Start Date*: 2007-03-16
    Sponsor Name:Southampton University Hospitals Trust (R&D)
    Full Title: The Use of Sulfasalazine as an Anti-fibrotic in Acute Alcoholic Hepatitis
    Medical condition: Acute Alcoholic Hepatitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019805 Hepatobiliary disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-005089-12 Sponsor Protocol Number: TRO19622 CL E Q 1159-1 Start Date*: 2008-02-05
    Sponsor Name:TROPHOS
    Full Title: Study title: Double-blind vs Placebo, Randomized, Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 500 mg QD for One Month in Patients with Non-Alcoholi...
    Medical condition: - Non Alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10053219 Non-alcoholic steatohepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001856-51 Sponsor Protocol Number: 12.007 Start Date*: 2014-08-26
    Sponsor Name:Aleksander Krag
    Full Title: Anti-fibrotic and molecular aspects of rifaximin in alcoholic liver disease: A randomized placebo controlled clinical trial
    Medical condition: Liver fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10016648 Fibrosis liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001983-31 Sponsor Protocol Number: GT-031 Start Date*: 2021-05-04
    Sponsor Name:Galectin Therapeutics Inc.
    Full Title: A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Es...
    Medical condition: Esophageal Varices in NASH Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10009214 Cirrhosis of liver without mention of alcohol LLT
    21.1 100000004856 10055489 Esophageal varices in cirrhosis of liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:12:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA